News Focus
News Focus
icon url

DewDiligence

02/10/19 4:15 PM

#17992 RE: biotech_researcher #17991

ELAN—One of the main arguments of the MF article (written in Oct 2018) is that it was hard to gauge Elanco’s financial performance based on historical financial data as a subsidiary of LLY. But this is no longer as pressing an issue now that ELAN has been spun off and its own (standalone) 4Q18 financials are available.

Moreover, ELAN’s share price has declined by about 15% since the MF article was written, making the valuation considerably more reasonable.